公开(公告)号：KR100927802B1

公开(公告)日：2009-11-23

申请号：KR1020070093994

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  전주홍 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철

IPC: A61K31/195 ,  A61K31/132 ,  A61P27/12

CPC classification number: A61K31/195

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cataract comprising (a) a therapeutically effective amount of a transglutaminase 2 (TGase2) inhibitor or N-acetylcysteine (NAC); and (b) a pharmaceutically acceptable carrier, and a method for screening a substance to prevent or treat cataract. The present invention definitely demonstrates molecular mechanism underlying cataractogenesis and provides a novel molecular target of cataract therapeutics. Moreover, the cataract therapeutics of this invention effectively prevent or treat cataract with much higher safety.

Abstract translation: 本发明涉及用于预防或治疗白内障的药物组合物，其包含（a）治疗有效量的转谷氨酰胺酶2（TGase2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可接受的载体，以及筛选预防或治疗白内障的物质的方法。 本发明明确证明了白内障发生的分子机制，并提供了一种新的白内障治疗分子靶点。 而且，本发明的白内障治疗剂有效地预防或治疗白内障具有更高的安全性。

公开(公告)号：KR100665976B1

公开(公告)日：2007-01-09

申请号：KR1020060004791

申请日：2006-01-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 강진모 ,  신동명 ,  김상준 ,  강흔수 ,  하종원

IPC: A01N1/00

CPC classification number: A01N1/0226

Abstract: Compositions for preserving internal organs are provided to interfere RhoA/ROCK cell signal transfer by inhibiting activity of TGase 2(transglutaminase 2), thereby preventing cell damage in the internal organs. The composition for preserving internal organs comprises cystamine, wherein the concentration of cystamine is 50-500 muM; the composition further comprises at least one component selected from osmotic pressure-controlling agent, ATP source, antioxidant and electrolyte ion; the osmotic pressure-controlling agent is hydroxyethyl starch, lactobionate or raffinose; the ATP source is adenosine or alpha-ketoglutarate; the antioxidant is glutathione or allopurinol; the electrolyte ion is sodium, potassium, magnesium or calcium ion; and the osmotic pressure of the composition is 300-350 mOsm/l.

Abstract translation: 提供保存内脏的组合物，通过抑制TGase 2（转谷氨酰胺酶2）的活性来干扰RhoA / ROCK细胞的信号传递，从而防止内脏器官的细胞损伤。 用于保存内脏的组合物包括胱胺，其中胱胺的浓度为50-500μM; 所述组合物还包含选自渗透压控制剂，ATP源，抗氧化剂和电解质离子中的至少一种成分; 渗透压控制剂是羟乙基淀粉，乳糖酸或棉子糖; ATP源是腺苷或α-酮戊二酸; 抗氧化剂是谷胱甘肽或别嘌呤醇; 电解质离子为钠，钾，镁或钙离子; 组合物的渗透压为300-350mOsm / l。

公开(公告)号：KR1020090028879A

公开(公告)日：2009-03-20

申请号：KR1020070093994

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  전주홍 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철

IPC: A61K31/195 ,  A61K31/132 ,  A61P27/12

CPC classification number: A61K31/195

Abstract: A pharmaceutical composition including a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC) is provided to suppress the outbreak of cataract and cure the cataract and to ensure high safety on organism. A pharmaceutical composition for preventing and treating cataract comprises (a) pharmaceutically effective dose of a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC); and (b)a pharmaceutically allowable carrier. The transglutaminase(TGase 2) inhibitor is the cystamine or the cysteamine.

Abstract translation: 提供包含转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）的药物组合物，以抑制白内障的发作并治愈白内障，并确保生物体的高安全性。 用于预防和治疗白内障的药物组合物包括（a）药学有效剂量的转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可允许的载体。 转谷氨酰胺酶（TGase 2）抑制剂是胱胺胺或半胱胺。

公开(公告)号：KR1020090028880A

公开(公告)日：2009-03-20

申请号：KR1020070093995

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철 ,  이동섭 ,  오근희 ,  김영환

IPC: A61K31/198 ,  A61K31/13 ,  A61P11/00 ,  A61P1/16

CPC classification number: A61K31/198

Abstract: A pharmaceutical composition including a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC) is provided to prevent or cure fibrosis and to specifically show the molecular mechanism about the fibrosis. A pharmaceutical composition for preventing and treating fibrosis comprises (a) pharmaceutically effective dose of a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC); and (b)a pharmaceutically allowable carrier. A screening method of a material for preventing and treating fibrosis comprises the steps of: (i) contacting a testing material with a transglutaminase(TGase 2) protein; and (ii) measuring the activity of the TGase 2. The transglutaminase(TGase 2) inhibitor is the cystamine or the cysteamine.

Abstract translation: 提供包含转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）的药物组合物，以预防或治愈纤维化，并具体显示纤维化的分子机制。 用于预防和治疗纤维化的药物组合物包括（a）药学有效剂量的转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可允许的载体。 用于预防和治疗纤维化的材料的筛选方法包括以下步骤：（i）使测试材料与转谷氨酰胺酶（TGase 2）蛋白质接触; 和（ii）测量TGase 2的活性。转谷氨酰胺酶（TGase 2）抑制剂是胱胺胺或半胱胺。